For the latest PBS indications for dulaglutide please see
https://www.pbs.gov.au/pbs/search?term=dulaglutide&search-type=medicines&analyse=false
- Trulicity should be administered once weekly on the same day. It can be given at any time of the day, without regard to meals. Trulicity should be injected subcutaneously in the abdomen, thigh, or upper arm.Do not inject Trulicity intravenously or intramuscularly.
- Renal impairment: No dose adjustment is required in individuals with renal impairment. However, there is limited experience in end-stage renal disease (creatinine clearance < 15 mL/min requiring dialysis treatment). Therefore, Trulicity cannot be recommended in this population.
- Use in Hepatic Impairment
- No dose adjustment is required based on hepatic impairment.
- No dose adjustment is required based on age.
Dulaglutide has not been studied in individuals with any form of severe gastrointestinal disease, including gastroparesis.
Note: Diabetes MedsCheck side effect profile, prevention of complications, referral to appropriate allied health care team.
Atrial fibrillation was experienced in trials compared to placebo.
Note: Diabetes MedsCheck for side effect profile with referral to GP if symptoms of this occur.
- Hypersensitivity to dulaglutide or any active ingredient
- Following subcutaneous injection, dulaglutide reaches peak plasma concentrations in 48 hours.
- Steady state plasma concentrations were achieved after 2 to 4 weeks of once weekly administration of dulaglutide 1.5 mg.
There does not seem to be any significantly relevant dose adjustment in this population.
For more detailed information on this product please consult the product information.
https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2015-PI-01412-1
For more detailed information on this product please consult the product information.
https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=PI&q=%20Dulaglutide&r=/